Pacira BioSciences Investors Advised to Join Class Action Over Stock Losses Following Patent Challenges
On March 10, 2025, The Gross Law Firm announced a potential class action lawsuit for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) concerning investment losses suffered during a critical period. Shareholders who acquired shares of Pacira between August 2, 2023, and August 8, 2024, are being encouraged to get in touch with the firm due to substantial declines in stock prices.
The catalyst for this legal initiative stems from a press release issued by Pacira on August 9, 2024, which revealed the unfavorable outcome of a patent infringement lawsuit against eVenus. The court's decision invalidated Pacira's U.S. Patent No. 11,033,495, crucially impacting Exparel, a drug that generates around 80% of the company's revenue. Analysts have expressed serious concerns that this ruling could also undermine the validity of other patents held by Pacira, paving the way for more generic competition and engendering additional litigation costs in the future.
Such revelations triggered a significant drop in Pacira's stock price, plummeting from $22.36 on August 8, 2024, to a staggering low of $11.70 per share by August 9, marking a staggering decline of over 47% in just a day.
Shareholders are urged to not delay their registration for this class action lawsuit, with the deadline set for March 14, 2025, to be considered for lead plaintiff status. However, being a lead plaintiff is not a prerequisite for participating in any potential recovery. Those who register will also have access to a portfolio monitoring software to stay updated on the status of the case throughout its duration.
The Gross Law Firm is a well-respected firm with a robust history of advocating for investor rights. Their commitment focuses on protecting investors who have suffered losses attributable to misleading or fraudulent practices. The firm aims to ensure corporate transparency and accountability, seeking recovery for damages incurred by investors victimized by a company's deceptive statements or omission of critical information that artificially inflated stock prices.
Those interested in participating in the class action can find further registration details at the Gross Law Firm's website. The provided link directs shareholders to a submission form where they can enter their information to secure a role in this potentially significant legal action.
In conclusion, if you invested in Pacira BioSciences during the specified timeframe and are troubled by recent developments, it's crucial to act swiftly to safeguard your rights and consider joining this class action lawsuit. Investors can take comfort in the reputable standing of The Gross Law Firm and its track record of supporting shareholder interests, making this a noteworthy opportunity for those adversely affected by the recent stock market fluctuations.
The catalyst for this legal initiative stems from a press release issued by Pacira on August 9, 2024, which revealed the unfavorable outcome of a patent infringement lawsuit against eVenus. The court's decision invalidated Pacira's U.S. Patent No. 11,033,495, crucially impacting Exparel, a drug that generates around 80% of the company's revenue. Analysts have expressed serious concerns that this ruling could also undermine the validity of other patents held by Pacira, paving the way for more generic competition and engendering additional litigation costs in the future.
Such revelations triggered a significant drop in Pacira's stock price, plummeting from $22.36 on August 8, 2024, to a staggering low of $11.70 per share by August 9, marking a staggering decline of over 47% in just a day.
Shareholders are urged to not delay their registration for this class action lawsuit, with the deadline set for March 14, 2025, to be considered for lead plaintiff status. However, being a lead plaintiff is not a prerequisite for participating in any potential recovery. Those who register will also have access to a portfolio monitoring software to stay updated on the status of the case throughout its duration.
The Gross Law Firm is a well-respected firm with a robust history of advocating for investor rights. Their commitment focuses on protecting investors who have suffered losses attributable to misleading or fraudulent practices. The firm aims to ensure corporate transparency and accountability, seeking recovery for damages incurred by investors victimized by a company's deceptive statements or omission of critical information that artificially inflated stock prices.
Those interested in participating in the class action can find further registration details at the Gross Law Firm's website. The provided link directs shareholders to a submission form where they can enter their information to secure a role in this potentially significant legal action.
In conclusion, if you invested in Pacira BioSciences during the specified timeframe and are troubled by recent developments, it's crucial to act swiftly to safeguard your rights and consider joining this class action lawsuit. Investors can take comfort in the reputable standing of The Gross Law Firm and its track record of supporting shareholder interests, making this a noteworthy opportunity for those adversely affected by the recent stock market fluctuations.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.